We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Transitioning from Using RUO to CGMP Chemicals for Clinical Trials

Scale to clinical trials with less risk
Credit: Thermo Fisher Scientific

The pressure of balancing budgetary and regulatory requirements can be challenging for new and emerging biopharma companies who want to be first to market with their molecule. 

When the biologic transitions into clinical trials, the use of GMP-quality materials in processes early is regarded as a best practice to help save valuable time and resources.

This whitepaper explores how transitioning from RUO to CGMP chemicals in processes early can help mitigate risks, streamline processes, and support efficient regulatory submissions to ultimately accelerate your journey towards commercialization.

Download this whitepaper to learn more about: 

  • What to expect when transitioning from RUO to CGMP
  • How to avoid time-consuming and costly pitfalls
  • Support from a qualified supply chain management company 
Brought to you by
Download Your Whitepaper for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.